CAR NK cell therapy for solid tumors: potential and challenges Statement of Significance This review highlights the promise of CAR NK cell therapy as a safer, off-the-shelf alternative to CAR-T cells for solid tumors.

Antibody Therapeutics (IF=4.5, Oxford University Press) ⚡ Review Highlight - CAR NK cell therapy for solid tumors: potential and challenges
academic.oup.com/abt/article/...
#antibodies #antibodydiscovery #antibodytherapeutics #biologics #naturalkillercells #CAR #CARNK

Reprogramming the tumor microenvironment: synergistic mechanisms of antibody–drug conjugates and immune checkpoint inhibitors Statement of Significance This study elucidates the synergistic mechanisms of antibody–drug conjugates and immune checkpoint inhibitors in tumor microenvir

Antibody Therapeutics (IF=4.5, Oxford University Press) ⚡ Reprogramming the tumor microenvironment: synergistic mechanisms of antibody–drug conjugates and immune checkpoint inhibitors
academic.oup.com/abt/article/...
#antibodydiscovery #tumormicroenvironment #TME

Analysis of the use of monoclonal antibodies in the treatment of Crohn’s disease Statement of Significance Despite clinical efficacy and safety, antibodies currently used for the treatment of Crohn’s disease have a number of limitations

Antibody Therapeutics (IF=4.5, Oxford University Press)
⚡ Review Highlight - Analysis of the use of monoclonal antibodies in the treatment of Crohn’s disease
academic.oup.com/abt/article/...
#Crohndisease #antibody #antibodytherapeutics #antibodydiscovery #antibodydevelopment

Don't have a favorite part of #antibodydiscovery? Maybe you'll find it in our 5 day #yeastdisplay course this summer!

Apply now — applications close March 30th ⏲️ buff.ly/oBlGknl

Interested in learning the basics of #yeastdisplaytechnology and #antibodydiscovery from leaders in the field? Join us in June for our hands-on 5-day course. Spots are limited — apply now: buff.ly/zrnlPN7

teaching a NEW short course at @PEGSummit Boston on May 12 — "The Dark Proteome: Unlocking Novel Targets for Next-Gen Biologics."
join me → pegsummit.com
#DarkProteome #pegsboston #proteinengineering #antibodydiscovery #biotherapeutics #drugdevelopment #pegsummit

2026 Yeast Display Technology for Antibody Discovery A five-day course in June 2026 combining lectures and hands-on laboratory sections to train participants in the core principles of yeast display technology.

Scientific progress is built on shared knowledge, accessible learning, and hands-on training. So this June we’re teaching a 5 day immersive course on the #yeastdisplay principles, applications and practical workflows that drive our #antibodydiscovery campaigns.

Apply by March 30 ⬇️
buff.ly/n8crLD0

MiXCR powered BCR extraction in this study, and with Platforma you can now go further—model structure, predict binding affinity, and rank top antibody leads by developability.

Learn more here: platforma.bio/antibody-dis...

#antibody #antibodydiscovery #antibodyengineering

Come work with us! IPI is seeking a #postdoctoralfellow to join us and apply our #antibodydiscovery platforms to cutting-edge questions in #cellsurface #proteinresearch and #antibodyengineering. It could be you!

Learn how to apply today: buff.ly/f2cLV4D

“What drives my research is the real-world impact that we make,” says Swethika Balasankar, a research associate on IPI’s #AntibodyDiscovery team.

Find out more about how IPI is shaping #proteinscience 🔬
buff.ly/Fd2qroB

Are you attending #PEGSEurope 2025 next week? Meet us at booth #249 to chat with our team, design a wizard trading card, and join contests for a chance to win exclusive prizes! Join our presentations for insights to empower your research: hubs.ly/Q03RsttC0

#PEGS2025 #PEGSummit #AntibodyDiscovery

Hello from the #PRIMESummit @cytiva.bsky.social! What an incredible opportunity to get into the details of #proteinpurification, #labautomation and #antibodydiscovery, right here in Boston!

Learn more about the IPI platform: buff.ly/zNIF9vw

It’s conference season! We're just back from AXON2025 & Discovery on Target where we: shared progress on antibodies to 50+ neuronal targets, discussed strategies for #membraneprotein and #GPCR discovery & met determined researchers in #braindevelopment #synapticplasticity #antibodydiscovery & more.

A huge thank you to @mofollp.bsky.social and West End Labs for bringing together leaders across science, technology and business to push the boundaries of what’s possible in NYC!

#MoForum #MachineLearning #Immunology #AntibodyDiscovery #AIForScience

Our CEO & Co-Founder @beckbrachman.bsky.social spoke at @mofollp.bsky.social #MoForum in NYC on how AI/ML is reshaping immunology and the opportunities ahead for life sciences — alongside amazing innovators! 🧠

#MachineLearning #Immunology #AIForScience #AntibodyDiscovery

Research at IPI directly impacts discovery — and this is a big part of what motivates IPI scientist Rebecca Hershman in the lab.

#proteinscience #proteomics #antibodydiscovery #proteininnovation 💪⚖️

buff.ly/HLvHdPR

Why antibody discovery needs to focus on function Early functional testing could transform the future of antibody-based therapies — here’s how.

Antibody-based immunotherapies can target disease with high precision — but #AntibodyDiscovery workflows are slow & costly.

Using streamlined functional analysis earlier in the discovery process can help deliver promising therapies quicker, writes our own Jonathan Didier.

go.lightcast.bio/47R6ZoF

The importance of negative training data for robust antibody binding prediction - Nature Machine Intelligence Thoughtfully designed negative training datasets may hold the key to more robust machine learning models. Ursu et al. reveal how negative training data composition shapes antibody prediction models an...

At IMPRINT, this mindset drives our push for robust AI-based mapping of adaptive immunity.

News & Views feature: doi.org/10.1038/s422...

#MachineLearning #Immunology #AntibodyDiscovery #AIForScience

#AntibodyDiscovery is at a turning point: traditional methods focused on binding rather than function are no longer sufficient.

By leveraging droplet #microfluidics our Envisia platform enables deeper analysis of cellular functions.

Learn more at our presentation @ the #FestivalofBiologics!

What drives protein science at IPI? We asked our team — and the answers totally wowed us!

We’re featuring their responses this fall, starting with IPI research associate Robert May. Come along with us on the ride!

#whatdrivesmyscience #proteinscience #bioscience #antibodydiscovery #research

Kling Bio partners with Sanofi to accelerate antibody discovery - PharmaTimes Collaboration aims to advance next-generation therapeutics and vaccines

#KlingBio #Sanofi #antibodydiscovery #vaccines #Bcellplatform #KlingSelect #monoclonalantibodies #humanviralpathogen #antiviraltherapies #vaccinedesign #Bcellimmortalisationandscreeningplatform #RSV #COVID19 #influenza #KlingSelectplatform
pharmatimes.com/news/kling-b...

Four ways Envisia is changing the game in antibody discovery By integrating single-cell analysis, multi-functional assays, and robust cell recovery into one seamless system, Lightcast empowers researchers to shift from a binding-first approach to a function-focused paradigm. Workflows on the Envisia platform has the potential to enhance lead quality, reduce attrition rates, and accelerate the discovery of antibodies with real therapeutic potential.

Our Envisia platform takes a function-focused approach to #AntibodyDiscovery, streamlining the discovery workflow with:

1️⃣ Real-time functional insights
2️⃣ Multi-assay screening
3️⃣ Faster hit identification & single-cell recovery
4️⃣ oEWOD technology to eliminate crosstalk

go.lightcast.bio/47w2EH3

Machining antibodies at IPI Very little these days escapes the reach of machine learning (ML) and, more broadly, artificial intelligence (AI). Antibodies have caught the AI train, as

What can we extract from our #antibody selection data? Certainly more — with #AI on our side. Read how IPI and collaborators @harvardmed.bsky.social applied #machinelearning and #artificialintelligence to streamline #antibodydiscovery for cell surface #antigens.
proteininnovation.org/2025/05/mach...

Phage Display Library Construction Process Steps

🎉 Service Launch: Phage Display Library Construction 🎉
We’re excited to introduce our Phage Display Library Construction service, designed to accelerate your antibody discovery, vaccine development, and protein interaction studies. 👉 Visit our page: rb.gy/erargh
#PhageDisplay #AntibodyDiscovery

Envisia Platform | Integrated Benchtop System for Functional Discovery Explore how the Envisia Platform combines a benchtop instrument, cartridge, and software to deliver end-to-end control for single-cell functional analysis. Designed to streamline setup, scale experime...

(3/3) The result? Accurate, functional antibody recovery ready for downstream sequencing and analysis.

Find out how Envisia can help your research in #DrugDiscovery, #AntibodyDiscovery and more: go.lightcast.bio/3FZ0zby

Four ways Envisia is changing the game in antibody discovery By integrating single-cell analysis, multi-functional assays, and robust cell recovery into one seamless system, Lightcast empowers researchers to shift from a binding-first approach to a function-foc...

Still relying on binding-focused approaches in #AntibodyDiscovery? You could be missing your best functional candidates. Envisia, our next-generation, single-cell platform, was designed to prioritise cellular & antibody functionality from the very start.

go.lightcast.bio/4k0KyQa

#ScienceSky 🧪

First yeast display course = complete ✅ We spent an impactful week exploring #yeastdisplay (library construction to FACS to NGS prep) with a curious, focused & thoughtful group.
Stay tuned—we’re just getting started! mailchi.mp/proteininnov...
#antibodydiscovery #proteinengineering

Why the Next Great Antibody May Come from a Droplet, Not a Mouse Spleen How a droplet-based system found sub-nanomolar antibodies in weeks, not months

Just wrote about a platform that pulled out 𝟱 𝘀𝘂𝗯-𝗻𝗮𝗻𝗼𝗺𝗼𝗹𝗮𝗿 antibodies in 3 weeks. From plasma cells, not display libraries.

Naturally paired, functionally diverse, and validated early (blockers, agonists, bins).

medium.com/@enginyapici...

#AntibodyDiscovery #DrugDiscovery #Microfluidics #Biotech

How can our benchtop Envisia platform accelerate #AntibodyDiscovery by bringing key cellular functions — including cytokine secretion, internalisation, and serial killing — into focus? Watch the video to learn more.

#ScienceSky 🧪 #AcademicSky #Microfluidics

www.youtube.com/watch?v=YctY...

Our #yeastdisplay for #antibodydiscovery course is off to a great start here on the Emmanuel College campus, with talks from IPI senior platform director André Teixeira, IPI scientist Deepash Kothiwal and Angela Reslow of Miltenyi Biotec yesterday! More learning to come!